- New Symbols to be Assigned for OTCBB Trading
PLANTATION, Fla., July 6 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex:
"VRA"; "VRA.U"; "VRA.WS") today announced that the American Stock Exchange
(Amex) has notified the Company that a Listing Qualifications Panel has
affirmed an Amex Staff determination to delist the Company's common stock,
units and warrants. Viragen's securities will continue to trade on the Amex
through July 11, 2007, and then are expected to begin trading on the
Over-the- Counter Bulletin Board (OTCBB) on July 12, 2007.
Viragen will announce the new trading symbols for OTCBB trading as soon
as they are assigned.
What is the OTC Bulletin Board?
The OTC Bulletin Board(R) (OTCBB) is a regulated quotation service that
displays real-time quotes, last-sale prices, and volume information in
over- the-counter (OTC) equity securities. An OTC equity security generally
is any equity that is not listed or traded on Nasdaq(R) or a national
securities exchange. OTCBB securities include national, regional, and
foreign equity issues, warrants, units, American Depositary Receipts
(ADRs), and Direct Participation Programs (DPPs). For more information,
please visit: http://www.otcbb.com
About Viragen, Inc.:
With international operations in the U.S., Scotland and Sweden, we are
a bio-pharmaceutical company engaged in the research, development,
manufacture and commercialization of therapeutic proteins for the treatment
of cancers and viral diseases. Our product portfolio includes:
Multiferon(R) (multi- subtype, human alpha interferon) which is uniquely
positioned in valuable niche indications, such as high-risk malignant
melanoma, and other select cancers and infectious diseases; VG102, a novel
monoclonal antibody that binds selectively to an antigen that is
significantly over-expressed on nearly all malignant tumors; and VG106, a
novel cytokine targeting difficult-to-treat cancers.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements
that can be identified by such terminology such as "believes," "expects,"
"potential," "plans," "suggests," "may," "should," "could," "intends," or
similar expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results to be materially different from any future results, performance or
achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to clinical trials and product development; availability of future
financing; unexpected regulatory delays or government regulation generally;
the success of third- party marketing efforts; our ability to retain
third-party distributors; our ability to obtain or maintain patent and
other proprietary intellectual property protection; and competition in
general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements
to reflect circumstances or events that occur after the date the
forward-looking statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com/
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications of
Viragen, Inc., +1-954-233-8746, Fax +1-954-233-1414, or E-mail
dcalder@viragen.com
|
